These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 11419670)

  • 21. The activity of grepafloxacin against respiratory pathogens in the UK.
    Wise R; Andrews JM
    J Antimicrob Chemother; 1997 Dec; 40 Suppl A():27-30. PubMed ID: 9484870
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The hidden impact of antibacterial resistance in respiratory tract infection. Re-evaluating current antibiotic therapy.
    Craig WA
    Respir Med; 2001 Jun; 95 Suppl A():S12-9; discussion S26-7. PubMed ID: 11419669
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Trends in antimicrobial susceptibility of bacterial pathogens of the respiratory tract.
    Doern GV
    Am J Med; 1995 Dec; 99(6B):3S-7S. PubMed ID: 8585554
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Resistance surveillance of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis isolated in the United States, 1997-1998.
    Thornsberry C; Jones ME; Hickey ML; Mauriz Y; Kahn J; Sahm DF
    J Antimicrob Chemother; 1999 Dec; 44(6):749-59. PubMed ID: 10590275
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Fluoroquinolones in respiratory infections.
    Klein NC
    Semin Respir Infect; 1991 Sep; 6(3):131-5. PubMed ID: 1754733
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Epidemiology of major respiratory pathogens.
    Debbia EA; Schito GC; Zoratti A; Gualco L; Tonoli E; Marchese A
    J Chemother; 2001 Nov; 13 Spec No 1(1):205-10. PubMed ID: 11936367
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Resistance surveillance of major pathogens for adult community-acquired respiratory tract infections in China: a multicenter study 2012].
    Zhao C; Zhang F; Wang Z; Cao B; Xu X; Sun H; Zhang R; Hu Y; Liu Z; Du Y; Chen R; Zhuo C; Su D; Liu Y; Hu B; Wang H
    Zhonghua Jie He He Hu Xi Za Zhi; 2015 Jan; 38(1):18-22. PubMed ID: 25791651
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Rational antibiotic therapy of acute upper respiratory tract infections].
    Mazur E
    Pol Merkur Lekarski; 2010 Nov; 29(173):304-8. PubMed ID: 21268914
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Clinical evaluation of meropenem in the pediatric field].
    Mikuni K; Matsuda H; Watanabe N
    Jpn J Antibiot; 1992 Jun; 45(6):738-43. PubMed ID: 1507405
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical efficacy and antimicrobial pharmacodynamics.
    Wise R
    Hosp Med; 2000 Jan; 61(1):24-30. PubMed ID: 10735149
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical resistance encountered in the respiratory surveillance program (RESP) study: a review of the implications for the treatment of community-acquired respiratory tract infections.
    Ehrhardt AF; Russo R
    Am J Med; 2001 Dec; 111 Suppl 9A():30S-35S discussion 36S-38S. PubMed ID: 11755441
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In vitro activity of the novel ketolide HMR 3647 and comparative oral antibiotics against Canadian respiratory tract isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis.
    Hoban DJ; Zhanel GG; Karlowsky JA
    Diagn Microbiol Infect Dis; 1999 Sep; 35(1):37-44. PubMed ID: 10529880
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of antimicrobial therapy on nasopharyngeal carriage of Streptococcus pneumoniae, Haemophilus influenzae, and Branhamella catarrhalis in children with respiratory tract infections.
    Varon E; Levy C; De La Rocque F; Boucherat M; Deforche D; Podglajen I; Navel M; Cohen R
    Clin Infect Dis; 2000 Aug; 31(2):477-81. PubMed ID: 10987708
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Moraxella catarrhalis: a review of an important human mucosal pathogen.
    Karalus R; Campagnari A
    Microbes Infect; 2000 Apr; 2(5):547-59. PubMed ID: 10865200
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical implications of resistance in the management of respiratory tract infections.
    Garau J
    Can Respir J; 1999; 6 Suppl A():23A-6A. PubMed ID: 10202229
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Quinolones and macrolides: roles in respiratory infections.
    Khan FA
    Hosp Pract (Off Ed); 1993 Jan; 28(1):149-153, 156-62. PubMed ID: 8380424
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Antimicrobial susceptibility of Streptococcus pyogenes, Haemophilus influenzae, Streptococcus pneumoniae and Moraxella catarrhalis from community acquired respiratory infections in 2000].
    Melo-Cristino J; Fernandes ML; Serrano N;
    Acta Med Port; 2001; 14(5-6):459-68. PubMed ID: 11878155
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Frequency of pathogen occurrence and antimicrobial susceptibility among community-acquired respiratory tract infections in the respiratory surveillance program study: microbiology from the medical office practice environment.
    Pfaller MA; Ehrhardt AF; Jones RN
    Am J Med; 2001 Dec; 111 Suppl 9A():4S-12S; discussion 36S-38S. PubMed ID: 11755437
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The PROTEKT surveillance study: antimicrobial susceptibility of Haemophilus influenzae and Moraxella catarrhalis from community-acquired respiratory tract infections.
    Hoban D; Felmingham D
    J Antimicrob Chemother; 2002 Sep; 50 Suppl S1():49-59. PubMed ID: 12239228
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Moraxella catarrhalis: clinical significance, antimicrobial susceptibility and BRO beta-lactamases.
    McGregor K; Chang BJ; Mee BJ; Riley TV
    Eur J Clin Microbiol Infect Dis; 1998 Apr; 17(4):219-34. PubMed ID: 9707304
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.